The return of EO9: A bioreductive indoloquinone targeted at bladder cancer

被引：0
|
作者：
Phillips, RM [1 ]
机构：
[1] Inst Canc Therapeut, Bradford, W Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS, DISTRIBUTION, AND METABOLISM OF THE NOVEL BIOREDUCTIVE ALKYLATING INDOLOQUINONE EO9 IN RODENTS
    WORKMAN, P
    BINGER, M
    KOOISTRA, KL
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (04): : 713 - 716
  • [2] CLINICAL-STUDIES WITH EO9, A NEW INDOLOQUINONE BIOREDUCTIVE ALKYLATING CYTOTOXIC AGENT
    VERWEIJ, J
    AAMDAL, S
    SCHELLENS, J
    KOIER, I
    LUND, B
    ONCOLOGY RESEARCH, 1994, 6 (10-11) : 519 - 523
  • [3] Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
    Schellens, JHM
    Dombernowsky, P
    Cassidy, J
    Epelbaum, R
    Dirix, L
    Cox, EH
    Wanders, J
    Calabresi, F
    Paridaens, R
    Monfardini, S
    Wolff, J
    Loos, WJ
    Verweij, J
    Pavlidis, N
    Hanauske, AR
    ANTI-CANCER DRUGS, 2001, 12 (07) : 583 - 590
  • [4] Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9
    Cummings, J
    Spanswick, VJ
    Gardiner, J
    Ritchie, A
    Smyth, JF
    BIOCHEMICAL PHARMACOLOGY, 1998, 55 (03) : 253 - 260
  • [5] Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
    Aamdal, S
    Lund, B
    Koier, I
    Houten, M
    Wanders, J
    Verweij, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (01) : 85 - 88
  • [6] EVALUATION OF THE CYTOTOXICITY OF THE INDOLOQUINONE EO9 IN A HUMAN COLON ADENOCARCINOMA MODEL
    BIBBY, MC
    CRONIN, BP
    PHILLIPS, RM
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 3 (04) : 661 - 666
  • [7] Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
    S. Aamdal
    B. Lund
    I. Koier
    M. Houten
    J. Wanders
    J. Verweij
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 85 - 88
  • [8] Radiosensitization of hypoxic tumors by the bioreductive agent apaziquone (EO9, EOquin™).
    Burd, R
    Lavorgna, SN
    Lenaz, L
    Reddy, G
    Kong, XG
    Wachsberger, PR
    Dicker, AP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9008S - 9008S
  • [9] Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9
    JonkmanDeVries, JD
    KettenesvandenBosch, JJ
    Henrar, REC
    Bult, A
    Beijnen, JH
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (02) : 181 - 191
  • [10] Development, pharmacology, role of DT-Diaphorase and prospects of the indoloquinone EO9
    SmitskampWilms, E
    Hendriks, HR
    Peters, GJ
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1996, 27 (03): : 421 - 429
12345